Pfiz­er delves in­to di­ver­si­ty-fo­cused clin­i­cal tri­al part­ner­ship

Just a few hours ago, Pfiz­er and dig­i­tal ther­a­peu­tics out­let Side­kick Health an­nounced a prod­uct launch in the next step of a pre-ex­ist­ing part­ner­ship. And now, the phar­ma gi­ant has a new part­ner­ship to an­nounce.

De­tails are few so far, but the part­ner­ship is with a glob­al clin­i­cal tri­al firm called Head­lands Re­search, which de­scribes it­self as an “in­ter­na­tion­al net­work of clin­i­cal tri­al sites.” The main ob­jec­tive, ac­cord­ing to a state­ment re­leased Thurs­day, is to start the ground work and ini­ti­ate re­search sites in ar­eas with di­verse pop­u­la­tions. Ac­cord­ing to a state­ment from Head­lands, that is part of its mis­sion to in­crease di­ver­si­ty among clin­i­cal tri­al par­tic­i­pants.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER